Timo Uphaus

Assistant Professor of Translational Neurology, JGU Mainz, Germany

[NeuroNews @NN_publishing]

The phenomenon of missing outcome data within #Stroke #Thrombectomy registries “is not a rare event and does not occur completely at random”, as per a recent @JNIS_BMJ report from @TimoUphaus, Marianne Hahn et al
https://t.co/IeqU9aJcGn

[Stroke AHA/ASA @StrokeAHA_ASA]

#STROKE August #EditorPick: Predictors of successful and futile recanalization in #EVT for M2 occlusions; #GermanStrokeRegistry. #AHAJournals https://t.co/qxF5UIgFut @BroocksGabriel @Fie0815 @WinkelmeierMD @MeyerL_MD @FabianFlottmann @uta_hanning

[Timo Uphaus @TimoUphaus]

Thanks to @EKFStiftung for dedicated research time to work on BBB and neuronal excitability in CNS disorders. @UnimedizinMainz @uni_mainz @NeurologyMainz

[Else Kröner-Fresenius-Stiftung @EKFStiftung]

Wir gratulieren PD Dr. Christoph Kuppe, Jun.-Prof. Dr. Timo Uphaus und apl. Prof. Dr. Philipp Vollmuth, MBA, die sich im Auswahlverfahren der #ClinicianScientist Professuren 2022 erfolgreich durchgesetzt haben. 🥳 https://t.co/3xCSScEGj9

[Ashkan Shoamanesh @Ash_Shoamanesh]

Excited to announce that the OCEANIC-STROKE trial (NCT0568607) led by @mcmasterstroke, @PHRIresearch & @BayerPharma has been officially launched with initial sites activated this week. A new paradigm in secondary stroke prevention with asundexian treatment awaits.
@mike_sharma2

[Timo Uphaus @TimoUphaus]

@DavidSeiffge @eva_mistry @TotoMynell @janpurrucker @Teddyyhwu Thanks for the possibility to participate.

[David Seiffge @DavidSeiffge]

Big thanks @eva_mistry for a well-balanced editorial https://t.co/XDvkleO048

Totally agree: time for more liberal, individualized decisions! Huge credits to @TotoMynell @janpurrucker @Teddyyhwu, Duncan Wilson and our fantastic global DO-IT collaboration

[Timo Uphaus @TimoUphaus]

@BiekeBroux @FWOVlaanderen @uhasselt @BIOMED_UHasselt @KennethVerboven Congrats!

[Heinz Wiendl @hwiendl]

Identifying CNS immunity: Can we use the CSF to inform about what is happening within the CNS? Our team led by Nicholas Schwab developed a framework and an app to analyze immune cells in the CSF or CNS. CSF can be used as a CNS biopsy "light"! https://t.co/fOpn7vvpJK

[Jacquie Shukaliak Quandt @jacquiequandt]

Kickoff of the @IntNatlWiMS Neuroimmunology/preclinical models/blood brain barrier/neuropathology interest group Dec 6. Bibi Bielekova & Catherine Larochelle https://t.co/TF3pGraq5d

[Timo Uphaus @TimoUphaus]

Huge international Initiative to improve secondary prophylactic treatment of Stroke. Thanks for the opportunity to collaborate. Curious about the results…

[Luciano Sposato 🇦🇷🇨🇦 @SposatoL]

Congratulations to all IMPROVE (International Multicenter Patent foRamen OVale & strokE) Registry Investigators [62 sites, 24 countries] on having completed the study enrolment at >3,500 patients this week! #NeuroTwitter #CardioTwitter @AntonioArauz2 @sheilambrasil @TimoUphaus

[Timo Uphaus @TimoUphaus]

@NeurologyMainz @VinzFleischer Congrats!

[Tudor G. Jovin, MD @TudorGJovin]

Another win for the democratization of thrombectomy. MR CLEAN late results just presented at @WorldStrokeOrg meeting showed benefit of EVT within 6-24 hrs when patients are selected based on presence of collaterals on CTA, rendering CTP, MRI & perfusion software non-essential.

[Else Kröner-Fresenius-Stiftung @EKFStiftung]

Prof. Dr. @chris_sohns , Prof. Dr. Philipp Sommer und Dr. @VanessaSciacca_ untersuchen die katheterbasierte Ablationsbehandlung von #Vorhofflimmern bei Patient:innen mit #Herzinsuffizienz vor und während der Listung zur #Herztransplantation.
https://t.co/lvfoIU6g6v

[World Stroke Org @WorldStrokeOrg]

📢Late Breaking #WSC2022 EAST-AFNET 4 Early rhythm control therapy for AF (within 12 months) in patients w/ history of stroke shown to lower recurrent stroke risk of 3.7 primary outcome events/100 person yrs vs 7.4 in usual care grp HR 0.52 (95% CI 0.29 – 0.93) in subgrp analysis

[Timo Uphaus @TimoUphaus]

Impact of COVID beyond incidence and death rates, which needed to be considered for visitation restriction in hospitals… Gerontology - https://t.co/qckoHZ3q9V @KargerPublisher @NeurologyMainz @UnimedizinMainz

[Timo Uphaus @TimoUphaus]

Thanks to Patients and all who contributed…#Revacept #STROKE

[Stroke AHA/ASA @StrokeAHA_ASA]

#STROKE Adjuvant #Revacept reduced the combined outcome of safety and efficacy in patients with symptomatic #ICAstenosis in a phase II placebo-controlled trial https://t.co/gTeQU6Rf0P @TimoUphaus

[Timo Uphaus @TimoUphaus]

Learn more about Lesion specifique thromobocyte inhibition in carotid artery disease by Revacept. It was a pleasure being interviewed by @NAsdaghi. Thanks for the possibility…

[Stroke AHA/ASA @StrokeAHA_ASA]

The September episode of the #StrokeAlert Podcast is now available. In this episode, host @NAsdaghi highlights articles in the Sept. issue of #Stroke and interviews @TimoUphaus about his article “Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis.”

[Universitätsmedizin Mainz @UnimedizinMainz]

Auf dem Weg in die Zukunft: Mit Investitionen von 2 Mrd. Euro in die Gebäudestruktur macht die Unimedizin Mainz einen entscheidenden Schritt hin zu einer der besten Kliniken Europas. Alle Infos zum Bau-Masterplan in der aktuellen PM:

https://t.co/bYAUtC75bc

#RLP #Mainz

[Timo Uphaus @TimoUphaus]

Stroke thrombectomy in clinical practice. Thanks to #GSR-ET collaborators and patients. #GoRedForWomen @SteffenTiedt @Dr_No_Charite @Fie0815 @UnimedizinMainz @DGNR_org @dgn_ev

[Stroke AHA/ASA @StrokeAHA_ASA]

#STROKE #OriginalResearch: Sex disparities in re-employment in stroke patients with large vessel occlusion undergoing mechanical thrombectomy #StrokeDisparities https://t.co/9oLgv9J6iX @TimoUphaus

[Seemant Chaturvedi @ChaturvediNeuro]

RESCUE-BT trial from China shows no benefit plus additional hazard of adding tirofiban prior to EVT. No effect on disability seen along with 3.3% incr. in symp ICH with tirofiban. Should be avoided in routine care
@svinsociety @ESOstroke @WorldStrokeOrg
https://t.co/3e5lEtbJHg